As oligonucleotide based therapeutics continue to advance rapidly — particularly in the area of injectable medicine — highly reliable analytical strategies are key for patient safety. Maintaining product quality, safety, and regulatory compliance across every development stage requires technologies capable of delivering robust, accurate, and comprehensive molecular insights.
This webcast explores how LC–MS can support the full oligonucleotide lifecycle, from early development to in process control, impurity monitoring and final regulatory release testing.
Participants will gain insights into how modern LC–MS systems provide end to end analytical confidence, enabling robust characterization and streamlined method development for modern injectables. Furthermore, an overview of the best practice implementation strategy is provided.
Join us to discover how a unified LC–MS approach can enhance decision making, deliver GMP conform data, and support stable quality insights for oligonucleotide based injectable medicine.